More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Mouse anti Human CD33

Mouse anti Human CD33

Research Use Only
0331
Nordic-MUbio
ApplicationsFlow Cytometry
Product group Antibodies
ReactivityHuman
TargetCD33
Price on request
100 ug
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    Nordic-MUbio
  • Product Name
    Mouse anti Human CD33
  • Delivery Days Customer
    7
  • Application Supplier Note
    PBMC: Add10 microl of MAB/10^6 PBMC in 100 microl PBS. Mix gently and incubate for 15 minutes at 2 to 8C. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add10 microl of MAB/100 microl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20C. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturers instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
  • Applications
    Flow Cytometry
  • Applications Supplier
    Flow Cytometry
  • Category Supplier
    Primary antibodies
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    FOS
  • Conjugate
    Unconjugated
  • Gene ID945
  • Target name
    CD33
  • Target description
    CD33 molecule
  • Target synonyms
    CD33 antigen (gp67); CD33 molecule transcript; gp67; myeloid cell surface antigen CD33; p67; sialic acid-binding Ig-like lectin 3; SIGLEC3; SIGLEC-3
  • Host
    Mouse
  • Isotype
    IgG1
  • Protein IDP20138
  • Protein Name
    Myeloid cell surface antigen CD33
  • Scientific Description
    CD33
  • Shelf life instruction
    See expiration date on vial
  • Reactivity
    Human
  • Reactivity Supplier
    Human
  • Reactivity Supplier Note
    CD33=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with FMY9S5 cells containing the CD33 gene.
  • UNSPSC
    12352203

References

  • 1. Comparsion of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. Garand, R., Vannier, J.P., Bene, M.C., Faure, G., Favre, M., Bernard, A,. Leukemia,1990 No;4(11):739-44. 2. Immunologic Classification of Leukemia and Lymphoma. Foon, K.A., Todd, III,R.F. (1986)(1986) Blood ,68, 1 3. Surface marker expression in acute myeloid leukaemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; TreilleRitouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4 4. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM; et al Blood 1992 May 1;79(9):2229-36 5. Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group. Dinndorf PA; Buckley JD; Nesbit ME; Lampkin BC; Piomelli S; Feig SA; Kersey JH; Hammond GD; Bernstein ID Med Pediatr Oncol 1992;20(3):192-200 6. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Bernstein ID; Singer JW; Smith FO; Andrews RG; Flowers DA; Petersens J; Steinmann L; Najfeld V; Savage D; Fruchtman S; et al Blood 1992 Apr 1;79(7):1811-6 7. The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry. Buccheri V; Shetty V; Yoshida N; Morilla R; Matutes E; Catovsky D Br J Haematol 1992 Jan;80(1):62-8